A 52-week, Double Blind, Double dummy, Randomized, Multinational, Multicentre, 3-arm Parallel Group, active Controlled Clinical Trial of fixed combination of beclometasone dipropionate plus formoterol fumarate plus glycopyrrolate bromide administered via pMDI (CHF 5993) versus tiotropium bromide and versus fixed combination of beclometasone dipropionate plus formoterol fumarate administered via pMDI and tiotropium bromide in patients with Chronic Obstructive Pulmonary Disease
Latest Information Update: 02 Feb 2023
At a glance
- Drugs Beclometasone/formoterol/glycopyrrolate (Primary) ; Beclometasone/formoterol; Tiotropium bromide
- Indications Chronic obstructive pulmonary disease
- Focus Registrational; Therapeutic Use
- Acronyms TRINITY
- Sponsors Chiesi Farmaceutici
- 19 Sep 2018 Results of a stratified safety pooled analysis of fatal adverse events (AEs) comparing extrafine ICS-containing combinations vs ICS-free treatments from TRILOGY, TRINITY and TRIBUTE studies presented at the 28th Annual Congress of the European Respiratory Society
- 23 May 2018 Results of safety pooled analysis using data from TRILOGY, TRINITY and TRIBUTE studies, presented at the 114th International Conference of the American Thoracic Society.
- 23 May 2018 Results of post hoc analysis comparing the effect of extrafine formulation of BDP/FF/G pMDI vs. either Tiotropium (TIO) or extrafine formulation of BDP/FF pMDI + TIO in COPD patients presented at the 114th International Conference of the American Thoracic Society